Estradiol Levels Predict Fracture Risk During the Menopausal Transition

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

FDA action date set for July 26, 2025.

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

Your daily dose of the clinical news you may have missed.